Small peptides that increase the number of BKCa channels on the surface of cells. BKCa channels have received considerable attention as therapeutic targets for a variety of conditions, including hypertension, asthma, erectile dysfunction, epilepsy, chronic pain, and urinary incontinence, among others.
This is a novel mechanism for drugs to affect these channels, and it should be more subtle and easier to control than agents that act by altering the gating properties of BKCa channels that are already in the cell membrane.
Pharmaceutical companies interested in ion channels as drug targets. Chemical companies that sell experimental reagents to physiologists, neuroscientists, and cell biologists.